John W Eikelboom Selected Research

apixaban

6/2022	Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban.
1/2022	Can a Single Measurement of Apixaban Levels Identify Patients at Risk of Overexposure? A Prospective Cohort Study.
1/2022	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review.
4/2021	Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES.
12/2020	Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation.
9/2020	Apixaban for Stroke Prevention in Atrial Fibrillation: Why are Event Rates Higher in Clinical Practice than in Randomized Trials?-A Systematic Review.
1/2020	Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials.
11/2019	Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence.
7/2017	Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial.
4/2017	Extended-duration versus short-duration pharmacological thromboprophylaxis in acutely Ill hospitalized medical patients: a systematic review and meta-analysis of randomized controlled trials.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John W Eikelboom Research Topics

Disease

158	Hemorrhage 11/2022 - 01/2002
134	Stroke (Strokes) 12/2022 - 04/2002
98	Atrial Fibrillation 09/2022 - 02/2004
53	Myocardial Infarction 12/2022 - 04/2002
41	Thrombosis (Thrombus) 01/2022 - 09/2003
38	Ischemic Stroke 01/2021 - 03/2003
36	Venous Thromboembolism 01/2022 - 07/2002
33	Acute Coronary Syndrome 01/2021 - 01/2002
32	Peripheral Arterial Disease 12/2022 - 08/2004
28	Cardiovascular Diseases (Cardiovascular Disease) 01/2021 - 01/2007
22	Coronary Artery Disease (Coronary Atherosclerosis) 12/2022 - 03/2010
21	Embolism (Embolus) 04/2021 - 05/2005
12	Vascular Diseases (Vascular Disease) 10/2022 - 01/2004
12	Thromboembolism 02/2022 - 09/2010
12	Venous Thrombosis (Deep-Vein Thrombosis) 12/2016 - 07/2002
11	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/2021 - 01/2012
10	Atherosclerosis 01/2022 - 01/2009
10	ST Elevation Myocardial Infarction 12/2010 - 01/2004
9	Coronary Disease (Coronary Heart Disease) 01/2022 - 03/2004
9	Pulmonary Embolism 11/2020 - 07/2002
8	Inflammation (Inflammations) 01/2022 - 01/2009
8	Neoplasms (Cancer) 01/2022 - 11/2002
7	Embolic Stroke 06/2022 - 03/2011
7	Heart Failure 01/2021 - 05/2012
7	Ischemia 01/2021 - 11/2011
6	Transient Ischemic Attack 11/2016 - 05/2008
5	Chronic Renal Insufficiency 01/2022 - 08/2012
5	Unstable Angina 01/2018 - 01/2005
4	COVID-19 01/2021 - 01/2020
4	Cognitive Dysfunction 10/2020 - 09/2008
4	Atherosclerotic Plaque (Atheroma) 01/2014 - 10/2006
4	Thrombocytopenia (Thrombopenia) 09/2012 - 10/2002
3	Vascular Calcification 11/2021 - 11/2012
3	Body Weight (Weight, Body) 01/2021 - 11/2009
3	Brain Infarction 10/2020 - 08/2016
3	Diabetes Mellitus 01/2020 - 01/2019
3	Renal Insufficiency (Renal Failure) 01/2018 - 10/2002
3	Osteoporosis 09/2013 - 10/2002
3	Chronic Kidney Failure (Chronic Renal Failure) 07/2013 - 10/2012
3	Hypertension (High Blood Pressure) 06/2012 - 01/2008

Drug/Important Bio-Agent (IBA)

98	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 12/2022 - 04/2002
91	AnticoagulantsIBA 02/2022 - 07/2002
68	Warfarin (Coumadin)FDA LinkGeneric 01/2020 - 07/2003
54	RivaroxabanIBA 12/2022 - 01/2011
46	Dabigatran FDA Link 06/2022 - 04/2010
31	Clopidogrel (Plavix)FDA Link 04/2019 - 06/2003
30	Vitamin K FDA Link 09/2021 - 10/2003
29	apixabanIBA 06/2022 - 03/2010
19	Heparin (Liquaemin)FDA LinkGeneric 07/2020 - 01/2002
14	Biomarkers (Surrogate Marker)IBA 01/2022 - 06/2016
11	Colchicine FDA LinkGeneric 01/2022 - 01/2012
10	CreatinineIBA 01/2022 - 05/2006
9	Factor Xa (Coagulation Factor Xa)IBA 01/2021 - 01/2009
9	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 01/2019 - 02/2004
9	HomocysteineIBA 09/2013 - 09/2004
9	Folic Acid (Vitamin M)FDA LinkGeneric 09/2013 - 08/2004
8	omega-Chloroacetophenone (Mace)IBA 10/2022 - 01/2018
8	Pharmaceutical PreparationsIBA 01/2022 - 09/2010
8	Factor Xa InhibitorsIBA 01/2021 - 11/2008
8	Enoxaparin (Lovenox)FDA LinkGeneric 01/2019 - 05/2006
8	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2019 - 06/2003
8	Vitamin B Complex (B Vitamins)IBA 09/2013 - 06/2008
7	Vitamin B 12 (Cyanocobalamin)FDA LinkGeneric 09/2013 - 02/2006
6	Hemostatics (Antihemorrhagics)IBA 06/2022 - 02/2013
6	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2022 - 07/2016
6	Fibrinolytic Agents (Antithrombotic Agents)IBA 01/2021 - 07/2008
6	Thrombin FDA Link 01/2020 - 03/2010
6	VitaminsIBA 09/2013 - 09/2004
6	Vitamin B 6IBA 09/2013 - 06/2008
6	Fondaparinux (Arixtra)FDA Link 12/2010 - 10/2007
5	PRT064445IBA 06/2022 - 01/2016
5	edoxabanIBA 06/2022 - 05/2014
5	Troponin T (Troponin T1)IBA 01/2022 - 06/2016
5	AntidotesIBA 01/2021 - 08/2013
5	AntithrombinsIBA 02/2016 - 01/2002
4	Hemoglobins (Hemoglobin)IBA 01/2022 - 08/2017
4	pro-brain natriuretic peptide (1-76)IBA 01/2022 - 11/2016
4	Growth Differentiation Factor 15IBA 11/2021 - 08/2017
4	N(4)-oleylcytosine arabinosideIBA 01/2018 - 07/2013
4	betrixabanIBA 04/2017 - 01/2014
4	bivalirudin (Angiomax)FDA Link 12/2015 - 01/2002
4	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 03/2014 - 10/2008
4	TabletsIBA 09/2013 - 06/2012
4	HirudinsIBA 09/2012 - 01/2002
3	plasma protein Z (protein Z)IBA 05/2020 - 10/2003
3	TroponinIBA 01/2020 - 01/2009
3	CholesterolIBA 01/2020 - 01/2014
3	fibrin fragment D (D-dimer)IBA 11/2017 - 12/2003
3	C-Reactive ProteinIBA 11/2016 - 03/2003
3	Cystatin CIBA 06/2016 - 06/2008
3	Prothrombin (Factor II)IBA 09/2013 - 04/2006

Therapy/Procedure

136	Therapeutics 10/2022 - 07/2003
21	Percutaneous Coronary Intervention 01/2021 - 01/2002
15	Stents 01/2021 - 05/2010
10	Secondary Prevention 01/2021 - 05/2008
7	Surgical Amputation (Amputations) 01/2021 - 08/2004
4	Drug Tapering 01/2022 - 01/2021
4	Thrombolytic Therapy 09/2009 - 01/2004
3	Polypharmacy 11/2022 - 01/2019
3	Length of Stay 07/2016 - 11/2010